AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12818245 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular weight heparin (LMWH) administered in a fixed dose of 200 anti-Xa IU/kg body weight in one subcutaneous injection daily
Number of subjects: 33
Study 12818245 — intervention group
Group type: EXPERIMENTAL
Intervention: Both OAT and LMWH
Number of subjects: 33
Study 10699698 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult self-inflatable bag (maximum volume, 1500 ml)
Number of subjects: 40
Study 10699698 — intervention group
Group type: COMPARATOR
Intervention: Paediatric self-inflatable bag (maximum volume, 700 ml)
Number of subjects: 40
Study 9330145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic-release technique
Number of subjects: 103
Study 9330145 — intervention group
Group type: COMPARATOR
Intervention: Conventional open release
Number of subjects: 103
Study 8418695 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) administered to the gastric bed (20 Gy using 11 to 15 MeV electrons)
Number of subjects: 41
Study 8418695 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (gastrectomy alone or resection and postoperative external beam radiotherapy to the upper abdomen (50 Gy using 6 to 10 mV photons))
Number of subjects: 41
Study 3674575 — intervention group
Group type: COMPARATOR
Intervention: 0.0 ppm SO2
Number of subjects: 85
Study 3674575 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ppm SO2
Number of subjects: 85
Study 3674575 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ppm SO2
Number of subjects: 85
Study 3674575 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 ppm SO2
Number of subjects: 85
Study 3674575 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise during exposure
Number of subjects: 85
Study 3674575 — intervention group
Group type: COMPARATOR
Intervention: 1 day or 1 week after exposure
Number of subjects: 85
Study 30404599 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar facet joint injections
Number of subjects: 50
Study 30404599 — intervention group
Group type: COMPARATOR
Intervention: Low dose computed tomography (CT) guidance for lumbar facet joint injections
Number of subjects: 50
Study 29046304 — intervention group
Group type: EXPERIMENTAL
Intervention: Look AHEAD
Number of subjects: 2404
Study 29046304 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP
Number of subjects: 2404
Study 26293583 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan 80 mg once daily for 10 weeks
Number of subjects: 170
Study 26293583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 23375194 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptor(®) Flavor Tabs(®) at a minimum dose of 0.5 mg/kg (0.23 mg/lb)
Number of subjects: 36
Study 23375194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel(®) Flavor Tabs(®) at a minimum dose of 0.5 mg/kg (0.23 mg/lb)
Number of subjects: 36
Study 23375194 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 36
Study 21968154 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic appendectomy
Number of subjects: 0
Study 21968154 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic appendectomy
Number of subjects: 0
Study 18001269 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard overnight TPN (0.16 gN.kg(‐1) of body weight.day(‐1) and 30 kcal.kg(‐1) of body weight.day(‐1))
Number of subjects: 12
Study 18001269 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 12
Study 20535793 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab treatment
Number of subjects: 0
Study 20535793 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 15748874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet taste
Number of subjects: 32
Study 15748874 — intervention group
Group type: EXPERIMENTAL
Intervention: Sour taste
Number of subjects: 32
Study 12013374 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific training in one of the conditions (resolved or unresolved harmonics)
Number of subjects: 0
Study 12013374 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 9917588 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum cementing technique (proximal and distal drainage)
Number of subjects: 70
Study 9917588 — intervention group
Group type: COMPARATOR
Intervention: Conventional cementing technique (control group)
Number of subjects: 70
Study 8048859 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 1.0 mg/h of tissue plasminogen activator (group A)
Number of subjects: 45
Study 8048859 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg bolus followed by an infusion of 1.0 mg/h of tissue plasminogen activator (group B)
Number of subjects: 45
Study 2972631 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) and etofenamate 10% gel, 3‐5 cm daily on the day of TENS therapy, and the same dose twice daily on the other days
Number of subjects: 30
Study 2972631 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 30
Study 31216821 — intervention group
Group type: COMPARATOR
Intervention: Quadruple therapy group
Number of subjects: 300
Study 31216821 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous probiotic group
Number of subjects: 300
Study 31216821 — intervention group
Group type: EXPERIMENTAL
Intervention: There after probiotic group
Number of subjects: 300
Study 27575011 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 16
Study 27575011 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 16
Study 27486173 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy after intravenous alteplase (IAT)
Number of subjects: 108
Study 27486173 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alteplase alone
Number of subjects: 108
Study 25186158 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated closed-loop insulin delivery
Number of subjects: 30
Study 25186158 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy
Number of subjects: 30
Study 21737235 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemodiafiltration (CVVHDF)
Number of subjects: 40
Study 21737235 — intervention group
Group type: COMPARATOR
Intervention: Intravenous furosemide
Number of subjects: 40
Study 21737235 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemodiafiltration (CVVHDF) and Intravenous furosemide
Number of subjects: 40
Study 20009055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarenflurbil, 800 mg, administered twice a day
Number of subjects: 1684
Study 20009055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1684
Study 17335419 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/mL rhBMP‐2
Number of subjects: 21
Study 17335419 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/mL rhBMP‐2
Number of subjects: 21
Study 17335419 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 21
Study 15128630 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic questionnaires
Number of subjects: 1333
Study 15128630 — intervention group
Group type: COMPARATOR
Intervention: Postal questionnaires
Number of subjects: 1333
Study 15128630 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge and practice questions
Number of subjects: 1333
Study 11511121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentasaccharide (low, medium, or high dose) administered daily for 5 to 7 days, intravenously on the first day, then subcutaneously
Number of subjects: 333
Study 11511121 — intervention group
Group type: COMPARATOR
Intervention: Pentasaccharide
Number of subjects: 333
Study 9683397 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (milk fermented by Lactobacillus acidophilus with 2.5% fructo-oligosaccharides, 0.5% vegetable oil, and 0.5% milk fat)
Number of subjects: 30
Study 9683397 — intervention group
Group type: COMPARATOR
Intervention: Reference product (traditional yogurt with 1% milk fat)
Number of subjects: 30
Study 7810083 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (Mg) treatment with 50 mmol Mg for the first 24 hours and 12 mmol Mg for the subsequent 24 hours
Number of subjects: 78
Study 7810083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 2898503 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate
Number of subjects: 0
Study 2898503 — intervention group
Group type: COMPARATOR
Intervention: povidone‐iodine
Number of subjects: 0
Study 2898503 — intervention group
Group type: COMPARATOR
Intervention: triclocarban medicated soap and water
Number of subjects: 0
Study 29128507 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloading shoes (ASICS GEL‐Melbourne OA)
Number of subjects: 164
Study 29128507 — intervention group
Group type: COMPARATOR
Intervention: Conventional shoes
Number of subjects: 164
Study 29128507 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloading shoes
Number of subjects: 164
Study 26878748 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% Rosuvastatin Gel
Number of subjects: 90
Study 26878748 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2% Atorvastatin Gel
Number of subjects: 90
Study 26878748 — intervention group
Group type: COMPARATOR
Intervention: Placebo Gel
Number of subjects: 90
Study 24560157 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH-style diet
Number of subjects: 57
Study 24560157 — intervention group
Group type: COMPARATOR
Intervention: Low-oxalate diet
Number of subjects: 57
Study 23883311 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline sulfate fast dissolving sublingual films
Number of subjects: 4
Study 23883311 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral tablets
Number of subjects: 4
Study 20664891 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dose of ethanol (35 g)
Number of subjects: 18
Study 20664891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17716753 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular dysfunction (RVD)
Number of subjects: 520
Study 17716753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of RV dilation and IVC broadening
Number of subjects: 520
Study 17716753 — intervention group
Group type: EXPERIMENTAL
Intervention: RVD, RVED/LVED ratio, SPAP
Number of subjects: 520
Study 17716753 — intervention group
Group type: EXPERIMENTAL
Intervention: RVED/LVED >0.67 and/or SPAP >60 mm Hg
Number of subjects: 520
Study 17716753 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic instability, 14-day clinical outcomes, SPAP
Number of subjects: 520
Study 17083839 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-adrenoceptor agonists
Number of subjects: 46
Study 17083839 — intervention group
Group type: COMPARATOR
Intervention: PFME
Number of subjects: 46
Study 11869839 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic lisinopril therapy
Number of subjects: 28
Study 11869839 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of lisinopril
Number of subjects: 28
Study 10022449 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐T4 treatment (group A, n = 100) with an initial dose of 150 microg daily
Number of subjects: 202
Study 10022449 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group B, n = 102)
Number of subjects: 202
Study 7784246 — intervention group
Group type: EXPERIMENTAL
Intervention: DGAVP (2 mg single dose)
Number of subjects: 0
Study 7784246 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with DGAVP (1 mg/day for 2 weeks)
Number of subjects: 0
Study 7784246 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic treatment with DGAVP
Number of subjects: 0
Study 7784246 — intervention group
Group type: COMPARATOR
Intervention: Acute treatment with DGAVP
Number of subjects: 0
Study 2207869 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen sodium (0.03%)
Number of subjects: 0
Study 359246 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 270
Study 359246 — intervention group
Group type: COMPARATOR
Intervention: Diflunisal 375 mg or 500 mg
Number of subjects: 270
Study 359246 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflunisal (multiple doses)
Number of subjects: 270
Study 359246 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 600 mg
Number of subjects: 270
Study 359246 — intervention group
Group type: COMPARATOR
Intervention: Oxyphenbutazone 200 mg t.i.d.
Number of subjects: 270
Study 359246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 29603100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary zinc intake (7.04 ± 4.28 mg/day)
Number of subjects: 0
Study 29603100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary zinc intake
Number of subjects: 0
Study 29603100 — intervention group
Group type: COMPARATOR
Intervention: Serum zinc concentration
Number of subjects: 0
Study 27311073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve tubes used for repair of 15 digital nerves and 13 median and ulnar nerves.
Number of subjects: 41
Study 27311073 — intervention group
Group type: COMPARATOR
Intervention: Primary end-to-end sutures without nerve tubes.
Number of subjects: 41
Study 27311073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve tubes used for repair of median and ulnar nerves.
Number of subjects: 41
Study 27311073 — intervention group
Group type: COMPARATOR
Intervention: Primary end-to-end sutures without nerve tubes for median and ulnar nerves.
Number of subjects: 41
Study 27311073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve tubes used for repair of finger injuries.
Number of subjects: 41
Study 27311073 — intervention group
Group type: COMPARATOR
Intervention: Primary end-to-end sutures without nerve tubes for finger injuries.
Number of subjects: 41
Study 25345953 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg, twice daily, n=36)
Number of subjects: 66
Study 25345953 — intervention group
Group type: COMPARATOR
Intervention: Acarbose (50 mg, three times a day, n=30)
Number of subjects: 66
Study 22707271 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (1.06 g)
Number of subjects: 50
Study 22707271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 22707271 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract
Number of subjects: 50
Study 20841390 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplement (1 mg/day)
Number of subjects: 871
Study 20841390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 871
Study 18947094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-run, physician-monitored clinics
Number of subjects: 23
Study 16822132 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal-navigator model for indoor navigation using a partially observable Markov decision process
Number of subjects: 0
Study 16822132 — intervention group
Group type: COMPARATOR
Intervention: Human navigation performance
Number of subjects: 0
Study 16822132 — intervention group
Group type: COMPARATOR
Intervention: Visual perception
Number of subjects: 0
Study 16822132 — intervention group
Group type: COMPARATOR
Intervention: Memory, spatial updating strategy, decision strategy
Number of subjects: 0
Study 12783370 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (Gleevec)
Number of subjects: 12000
Study 10893682 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 100
Study 10893682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9294801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (IM)
Number of subjects: 2
Study 9294801 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous pinning (PP)
Number of subjects: 2
Study 8421719 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft foot orthotics in addition to an exercise program
Number of subjects: 20
Study 8421719 — intervention group
Group type: COMPARATOR
Intervention: Exercise program (control group)
Number of subjects: 20
Study 3534570 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (100 mg three times daily)
Number of subjects: 60
Study 3534570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3534570 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 60
Study 29193558 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (SIs), 6.5 to 8.5mm long
Number of subjects: 52
Study 29193558 — intervention group
Group type: COMPARATOR
Intervention: Sinus augmentation (SA) and implants ≥10mm long
Number of subjects: 52
Study 29193558 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (SIs)
Number of subjects: 52
Study 29193558 — intervention group
Group type: COMPARATOR
Intervention: Sinus augmentation (SA)
Number of subjects: 52
Study 29193558 — intervention group
Group type: EXPERIMENTAL
Intervention: Short implants (SIs) and Sinus augmentation (SA)
Number of subjects: 52
Study 27362788 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir (TFV) 1% gel
Number of subjects: 248
Study 27362788 — intervention group
Group type: COMPARATOR
Intervention: Placebo rectal gel
Number of subjects: 248
Study 24377326 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (low dose: 5 mg × 3)
Number of subjects: 29
Study 24377326 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (normal dose: 20 mg × 3)
Number of subjects: 29
Study 24377326 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 29
Study 22430907 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Extraperitoneal Inguinal Hernioplasty (TEP)
Number of subjects: 660
Study 22430907 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 660
Study 19765066 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive distance running (ER)
Number of subjects: 24
Study 19765066 — intervention group
Group type: COMPARATOR
Intervention: Sedentary controls (SC)
Number of subjects: 24
Study 18370580 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly reflexology treatments for 4 weeks
Number of subjects: 21
Study 18370580 — intervention group
Group type: COMPARATOR
Intervention: Friendly visits for 4 weeks (Control)
Number of subjects: 21
Study 16201210 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency noise (LFN) at 50 dB(A)
Number of subjects: 96
Study 16201210 — intervention group
Group type: COMPARATOR
Intervention: Reference noise (broadband noise without dominant low frequency content) at 50 dB(A)
Number of subjects: 96
Study 11684984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 66
Study 11684984 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 66
Study 11684984 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 66
Study 9727786 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus education (Exercise group)
Number of subjects: 126
Study 9727786 — intervention group
Group type: COMPARATOR
Intervention: Education (Control group)
Number of subjects: 126
Study 7949827 — intervention group
Group type: EXPERIMENTAL
Intervention: Proper diagnosis and treatment of hypertensive disorders in pregnancy
Number of subjects: 0
Study 3056431 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg bid
Number of subjects: 16
Study 3056431 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate 1000 mg bid
Number of subjects: 16
Study 3056431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19333169 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine-bupivacaine nerve-stimulator guided injection (9 mL bupivacaine 0.5% and 1 mL clonidine 150 mcg/mL)
Number of subjects: 80
Study 19333169 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine guided injection (9 mL bupivacaine 0.5% and 1 mL saline)
Number of subjects: 80
Study 290650 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphates added to pre-sweetened and non-presweetened ready-to-eat cereals
Number of subjects: 145
Study 290650 — intervention group
Group type: COMPARATOR
Intervention: Non-cereal eaters
Number of subjects: 145
Study 31937730 — intervention group
Group type: EXPERIMENTAL
Intervention: ASHAs with monetary incentive
Number of subjects: 162
Study 31937730 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education (HE)
Number of subjects: 162
Study 31780418 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel as mono antiplatelet therapy (MAPT) after COBRA PzF NCS implantation
Number of subjects: 77
Study 28494920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2 mg/0.05 mL at baseline, 4 weeks, and 8 weeks; reviewed every 4 weeks thereafter with injections as needed)
Number of subjects: 232
Study 28494920 — intervention group
Group type: COMPARATOR
Intervention: PRP standard care (single spot or multispot laser at baseline, fractionated fortnightly thereafter, assessed every 8 weeks and treated as needed)
Number of subjects: 232
Study 25986590 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium plus Treatment As Usual (TAU)
Number of subjects: 0
Study 25986590 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Treatment As Usual (TAU)
Number of subjects: 0
Study 23870047 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet administration of the Edinburgh Depression Scale
Number of subjects: 91
Study 23870047 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administration of the Edinburgh Depression Scale
Number of subjects: 91
Study 23870047 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen-and-paper administration of the Edinburgh Depression Scale
Number of subjects: 91
Study 23870047 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison across all groups
Number of subjects: 91
Study 21341893 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted one-session treatment (OST-CA)
Number of subjects: 0
Study 21341893 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard one-session treatment (OST-S)
Number of subjects: 0
Study 21341893 — intervention group
Group type: COMPARATOR
Intervention: Self-help control
Number of subjects: 0